[go: up one dir, main page]

WO2001030391A3 - Pharmaceutical composition containing midazolam - Google Patents

Pharmaceutical composition containing midazolam Download PDF

Info

Publication number
WO2001030391A3
WO2001030391A3 PCT/IB2000/001525 IB0001525W WO0130391A3 WO 2001030391 A3 WO2001030391 A3 WO 2001030391A3 IB 0001525 W IB0001525 W IB 0001525W WO 0130391 A3 WO0130391 A3 WO 0130391A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition containing
midazolam
containing midazolam
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/001525
Other languages
French (fr)
Other versions
WO2001030391A2 (en
Inventor
Lawrence John Penkler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmarc Nederland BV
Original Assignee
Farmarc Nederland BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmarc Nederland BV filed Critical Farmarc Nederland BV
Priority to AU79375/00A priority Critical patent/AU7937500A/en
Publication of WO2001030391A2 publication Critical patent/WO2001030391A2/en
Publication of WO2001030391A3 publication Critical patent/WO2001030391A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition for transmucosal delivery comprises an aqueous solution of an inclusion complex of midazolam and a water-soluble substituted beta-cyclodextrin. The solution contains from 2 to 20 mg/ml of midazolam and has a pH of from 4 to 7.
PCT/IB2000/001525 1999-10-27 2000-10-24 Pharmaceutical composition containing midazolam Ceased WO2001030391A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU79375/00A AU7937500A (en) 1999-10-27 2000-10-24 Pharmaceutical composition containing midazolam

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA99/6756 1999-10-27
ZA996756 1999-10-27

Publications (2)

Publication Number Publication Date
WO2001030391A2 WO2001030391A2 (en) 2001-05-03
WO2001030391A3 true WO2001030391A3 (en) 2001-12-20

Family

ID=25587963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001525 Ceased WO2001030391A2 (en) 1999-10-27 2000-10-24 Pharmaceutical composition containing midazolam

Country Status (2)

Country Link
AU (1) AU7937500A (en)
WO (1) WO2001030391A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803240D0 (en) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB0130964D0 (en) 2001-12-24 2002-02-13 Special Products Ltd Pharmaceutical composition
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
GB0423800D0 (en) * 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
EP2106786A1 (en) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmaceutical preparation comprising permethylated cyclodextrin
GB2481407B (en) * 2010-06-22 2012-05-23 Special Products Ltd A rapid onset liquid midazolam composition for buccal administration
WO2014075935A1 (en) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
KR102164174B1 (en) 2012-12-11 2020-10-12 자피오텍 게엠베하 Delphinidin for combating melanoma cells
WO2020129085A1 (en) 2018-12-18 2020-06-25 Cipla Limited Intranasal formulation
CN113209013B (en) * 2021-06-24 2023-04-07 新疆特丰药业股份有限公司 Midazolam liquid preparation and preparation method and application thereof
EP4442249A1 (en) * 2023-04-06 2024-10-09 B. Braun Melsungen AG Unit dosage composition comprising midazolam

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002518A1 (en) * 1992-07-27 1994-02-03 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0657176A2 (en) * 1993-12-06 1995-06-14 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
WO1999042111A1 (en) * 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002518A1 (en) * 1992-07-27 1994-02-03 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0657176A2 (en) * 1993-12-06 1995-06-14 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
WO1999042111A1 (en) * 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LOFTSSON T. ET AL: "Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 212, January 2001 (2001-01-01), pages 29 - 40, XP001023911 *
MERKUS F W H M ET AL: "CYCLODEXTRINS IN NASAL DRUG DELIVERY", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 36, no. 1, 1 March 1999 (1999-03-01), pages 41 - 57, XP001023913, ISSN: 0169-409X *
ROELOFSE JA.: "Intranasal midazolam spray in adults-pharmacokinetics and clinical use", SAJAA, June 2000 (2000-06-01), XP001025564 *
SIGURJÓNSDÓTTIR J. F. ET AL: "Formulation and preliminary clinical testing of midazolam-cyclodextrin nasal spray", PROCEED. INT'L SYMP. CONTROL. REL. BIOACT. MATER, vol. 27, 2000, pages 700 - 701, XP001025500 *
THUM P ET AL: "MIDAZOLAM GIVEN AS AN INTRANASAL SPRAY IN CHILDREN", BRITISH JOURNAL OF ANAESTHESIA, BJM PUBLISHING GROUP, LONDON, GB, vol. 81, no. 1, July 1998 (1998-07-01), pages 100 - 101, XP001023963, ISSN: 0007-0912 *

Also Published As

Publication number Publication date
AU7937500A (en) 2001-05-08
WO2001030391A2 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
MX9709094A (en) Pharmaceutical formulations of highly lipophilic camptothecin derivatives.
IL133397A (en) Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin
ES2181055T3 (en) GALENIC FORMULATIONS CONTAINING OPTIACE ANTAGONISTS.
EP1246608A4 (en) Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
WO2001030391A3 (en) Pharmaceutical composition containing midazolam
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
WO2002074238A3 (en) Water soluble and palatable complexes
MY111136A (en) Oral formulations of an antifungal.
AU2002350592A1 (en) Ph-sensitive polymer
AU2002211018A1 (en) Cellulosic particle for pharmaceutical preparation
WO2001041737A3 (en) Solid oral dosage form
HK1045940A1 (en) Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
WO2001066601A8 (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
AU1735001A (en) Cyclodextrin-containing pharmaceutical composition
CA2270177A1 (en) Transdermal administration of ment
PL346764A1 (en) New oral formulation for 5-ht4
AU2001238346A1 (en) Modification of biopolymers for improved drug delivery
MY135548A (en) Aqueous preparation containing oligopeptides and etherified cyclodextrin
WO2000076528A3 (en) Pharmaceutical preparation containing proteins
AU4061599A (en) Aqueous preparations containing hardly soluble drug
AU2847700A (en) Internet content delivery acceleration system
ZA200203078B (en) Ciclesonide-containing aqueous pharmaceutical composition.
AU1776801A (en) Modular targeted liposomal delivery system
WO2002076376A3 (en) A stable pharmaceutical composition of pravastatin
AU5961300A (en) Algae protein polysaccharide extraction and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP